RNA splicing factors as oncoproteins and tumour suppressors.
about
Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells.SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeastHow do messenger RNA splicing alterations drive myelodysplasia?Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.A novel BMX variant promotes tumor cell growth and migration in lung adenocarcinoma.Jmjd6, a JmjC Dioxygenase with Many Interaction Partners and Pleiotropic FunctionsIdentification of differentially expressed splice variants by the proteogenomic pipeline Splicify.BPP: a sequence-based algorithm for branch point prediction.Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.Therapeutic targeting of splicing in cancer.Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability.Splicing factor gene mutations in hematologic malignancies.Modulation of aberrant splicing in human RNA diseases by chemical compounds.Splicing Factor Mutations in Myelodysplasias: Insights from Spliceosome Structures.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.RNA editing-dependent epitranscriptome diversity in cancer stem cells.The role of RNA alternative splicing in regulating cancer metabolism.Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.Congenital myotonic dystrophy-an RNA-mediated disease across a developmental continuum.Machine Learning-Assisted Network Inference Approach to Identify a New Class of Genes that Coordinate the Functionality of Cancer NetworksThe role of alternative splicing in cancer.The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing.PRPF8 is important for BRCA1-mediated homologous recombination.Molecular basis of differential 3' splice site sensitivity to anti-tumor drugs targeting U2 snRNP.Signaling Pathways Driving Aberrant Splicing in Cancer Cells.Expanding horizons: new roles for non-canonical RNA-binding proteins in cancer.Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF.Cancer-Associated Mutations Mapped on High-Resolution Structures of the U2AF2 RNA Recognition Motifs.Emerging roles of hnRNPA1 in modulating malignant transformation.Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes.Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma.CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB.Insights from structures of cancer-relevant pre-mRNA splicing factors.Spliceosomal components protect embryonic neurons from R-loop-mediated DNA damage and apoptosis.The Augmented R-Loop Is a Unifying Mechanism for Myelodysplastic Syndromes Induced by High-Risk Splicing Factor Mutations.Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.Most human introns are recognized via multiple and tissue-specific branchpoints.
P2860
Q30252566-3F8FBB6C-049D-4C85-A8AA-61C908DE85D0Q33635951-BF62EDCF-99C1-4CC2-A4D9-9DEDF61E09FDQ33640195-9D9731F2-1EAF-4D70-9DD1-FB9677C69F0EQ33703520-DCCA7B95-8745-491E-A5E3-0216F0FA988BQ33779499-F80B31D6-51AB-4B60-BFB0-3BB4D3798A21Q37703058-D40BA75A-BD54-4A2F-BAA4-B81865BF96EDQ38659439-A1726B47-5CA7-4E20-B5A1-E2D6B2C86594Q38716866-0E4D974B-0653-4DA1-B6AA-F30C65B9D554Q38735423-AE06422F-EECD-4254-923A-B4EB7066AAB6Q38948363-27C519A0-3C60-4E05-A12B-1441538D3D62Q38972458-1DF6313C-9030-48EE-A634-CC0A906E707CQ39035441-E4629873-A78A-418B-89A1-EBF93EA12B35Q39212263-E9568C38-E341-4CAA-B024-1708CDAC4602Q39217354-DE3B67F3-9FE6-47A1-ABDE-74DB975C174CQ39243052-1B4AB647-F5EE-422F-BA64-02A269EB5923Q39247132-C400A050-807C-4C18-B891-30842060CA31Q39253959-F5D7F160-16FF-4C28-82D8-3727DE69A0DAQ39279998-D7DD62C9-93F7-4665-BA91-4A6DD7FB5D5BQ39440318-0F7BE16A-3EBB-4DEF-9126-5BC535E79486Q41204513-330919F9-68DD-4721-BA15-6F0920389CCAQ42282317-27B50B6B-3EF0-4C3A-9547-793B33490A67Q42658896-E8D0CC3B-3D8A-413D-B963-7DB759B624B7Q47096369-5521FCE5-1E0B-442F-8199-32222A34A74CQ47121434-64FF7C1D-CCDC-4ACA-A89E-4F659B3F9A31Q47246029-6A9BF6B8-1794-4FB5-AEBC-B2FB4171BF5BQ47319130-3E56F345-B842-471E-AAE9-FF26D9A50502Q47784889-3582466C-6F7D-4C67-BEE2-1B42C7BD8B5EQ47820506-51A0F0AF-C8B9-4124-A507-7793A6BA4091Q47889480-798B10BA-28BA-4E58-B1AD-CB4E396B4C4AQ47974502-BD41C30D-A121-43BC-931D-A2379350C059Q48113959-1305FB09-F767-4388-89B3-A11595B95D3EQ48149987-D4CFBE17-6AFB-40DE-A46D-A31D4C310157Q49363972-75E3F0EA-6843-4A80-AD70-333A7A865950Q49698247-F056CD6E-40CC-42E3-ABAC-84AC976A4EB6Q50055209-FE1E452C-88B6-41EB-9390-FF4345B0D19CQ50057508-1C4CAD17-7736-4D99-B869-A38CB42BCABFQ50118960-7CC7EB56-0AEE-407D-8411-4AD646A1691AQ50209871-E2254447-1538-4C65-826F-1D4D34A86BF1Q52313265-8153A4DC-5CBA-482F-83E3-BCA9E82C93FFQ52318754-D5C50BCA-783D-4476-8B7E-33334CE7F5A4
P2860
RNA splicing factors as oncoproteins and tumour suppressors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RNA splicing factors as oncoproteins and tumour suppressors.
@en
RNA splicing factors as oncoproteins and tumour suppressors.
@nl
type
label
RNA splicing factors as oncoproteins and tumour suppressors.
@en
RNA splicing factors as oncoproteins and tumour suppressors.
@nl
prefLabel
RNA splicing factors as oncoproteins and tumour suppressors.
@en
RNA splicing factors as oncoproteins and tumour suppressors.
@nl
P2860
P50
P356
P1476
RNA splicing factors as oncoproteins and tumour suppressors.
@en
P2093
Omar Abdel-Wahab
P2860
P2888
P304
P356
10.1038/NRC.2016.51
P407
P577
2016-06-10T00:00:00Z